Fujifilm Growth Strategy with the Acquisition of Wako Pure Chemical Industries
|
|
- Aubrey Wiggins
- 6 years ago
- Views:
Transcription
1 Fujifilm Growth Strategy with the Acquisition of Wako Pure Chemical Industries FUJIFILM Holdings Corporation Chairman and Chief Executive Officer Shigetaka Komori December 15, 2016
2 Key Business Areas Expanding Business in Six Priority Areas Healthcare Graphic Systems Digital Imaging Highly Functional Key Materials Business Areas Document Solutions Optical Devices 1
3 Overview of Wako Pure Chemical Industries, Ltd. Company Name: Incorporation: 1922 Business Overview: Revenue: Wako Pure Chemical Industries, Ltd. Chemicals Department of Takeda Pharmaceutical separated and established as Takeda Pure Chemical Ltd. Manufacturing and sales of laboratory chemicals, clinical diagnostic reagents and speciality chemicals JPY 79.4 billion (FY2016/3, Consolidated) Clinical Diagnostic Reagents JPY 26.0bn Laboratory Chemicals JPY 36.6bn Speciality Chemicals JPY 16.7bn 2
4 Objectives and Purposes of Acquisition Graphic Systems Digital Imaging Healthcare Clinical Diagnostic Reagents Key Business Areas Laboratory Chemicals Highly Functional Materials Speciality Chemicals Optical Devices Document Solutions 3
5 Objectives and Purposes of Acquisition Technology fusion of Fujifilm and Wako Healthcare Advancement of medical applications in regenerative medicines Improvement quality of medical care through widespread use of In-Vitro Diagnostics Industrial Contribution to advancement of cutting edge technology in semiconductor industry Creating innovation with development of new highly functional materials Stable supply of high quality pharmaceuticals through expansion of contract manufacturing Addressing Social Challenges 4
6 The Acquisition of Wako Pure Chemical Industries FUJIFILM Holdings Corporation President and Chief Operation Officer Kenji Sukeno December 15, 2016
7 Business Overview of Wako Pure Chemical Laboratory Chemicals related to: Cell culture medium DNA/Protein research Analysis of environment/food area Organic synthesis, etc. Clinical Diagnostics Reagents Revenue: JPY36.6bn (46% of total) For automated bio chemical analyzer, etc. For immune system and microorganism, etc. Speciality Chemicals Revenue: JPY26.0bn (33% of total) Revenue: JPY16.7bn (21% of total) Semiconductor Materials (detergent for post CMP process, etc.) Azo polymerization initiator for superabsorbent polymer Pharmaceutical intermediate, etc. Clinical Diagnostics Reagents Laboratory Chemicals Specialty Chemicals 6
8 Expected Synergies through the Acquisition Expanding Healthcare Business 1) Regenerative Medicine 2) In-Vitro Diagnostics 3) Pharmaceutical Contract Development and Manufacturing Organization(CDMO) Expanding Highly Functional Materials Business 1) Electronic Materials 2) Industrial Products 7
9 The Three Key Components for Regenerative Medicine Cell Scaffold (recombinant peptide) Cell Culture Medium Cytokine Fujifilm group to own all three key components for regenerative medicine 8
10 Regenerative Medicine Business Scaffold (recombinant peptide) Patent & Know-how for Cell Production and Cultivation 画像診断技術 Development/ Manufacturing of ips Cell Development/ Manufacturing of Regenerative Medicine Products Cell Culture Medium Manufacturing Technology GMP Certified Manufacturing Facilities Dispersion/Synthesis Technology Expanding Regenerative Medicine Business 9
11 In-Vitro Diagnosis (Medical System Business) Clinical Chemical Analysis System Immunodiagnosis System Global Business Platform through Medical Devices < 和光純薬 > 免疫分析装置 System 生化学分析試薬国内の営業網 Immune Analysis Laboratory Chemicals for Biochemical Analysis Extensive Sales Network with Access to Clinical Facilities in Japan Promoting In-Vitro Diagnostic Products Developing high-functional In-Vitro Diagnostic Products 10
12 Pharmaceutical CDMO (Pharmaceutical Business) Chemical Synthesis Technology of Small Molecule Drugs FUJIFILM Finechemicals Biopharmaceutical Manufacturing Technology Biopharmaceutical CDMO Small Molecule Drugs CDMO < 和光純薬 > Chemical 免疫分析装置 Synthesis Technology 生化学分析試薬国内の営業網 Cell Culture Medium Manufacturing Technology Vast Sales Network to Capture Client Needs Expanding Pharmaceutical CDMO business 11
13 Highly Functional Materials (Electronic Materials Business) Photoresist CMP Slurry Materials for Image Sensor, etc. < 和光純薬 > 免疫分析装置生化学分析試薬国内の営業網 High Purity Cleaning Agent High Quality Etching Solution Non-Ionic Surfactants, etc. Wafer (face down) Load CMP Slurry Polishing Pad Rotating Head Rotating Plate CMP Process Accelerating Electronic Materials Business 12
14 Highly Functional Materials Synergy (Industrial Products Business) Chemical Synthesis Technology Analysis Technology Library of 200,000 chemical compounds Strong Global Business Platform < 和光純薬和光純薬 > 重合開始剤等免疫分析装置 Polymerization 生化学分析試薬 Initiator 国内の営業網 Vast Polymeric Material Domestic and Global Speciality Chemical Manufacturing Sites Expanding Speciality Chemicals Business Globally 13
15 Overview of Acquisition Acquisition Structure: Tender Offer Price: Tender Offer for shares of Wako Pure Chemical Industries, Ltd. by FUJIFILM Corporation JPY 8,535 per share Expected Amount of Funds Necessary for Tender Offer: Approximately JPY154.7 billion Expected Schedule: Feb.27 Apr.3 Apr.21 Tender offer period for Wako shares Settlement of Tender Offer (consolidation of Wako) In the event of successful completion of the Tender Offer, Wako will be a consolidated subsidiary of Fujifilm Holdings on Apr. 21, Therefore, we expect no impact on Fujifilm Holdings FY2017/3 consolidated financial results. We will announce the impact for FY2018/3 consolidated financial results once details are confirmed. 14
16 Revenue Target of Wako Pure Chemical After Acquisition To Achieve JPY 100billion in Revenue by FY2022/3 Further Growth (JPY bn) Specialty Chemicals Clinical Diagnostics Reagents Laboratory Chemicals 15
17
Innovating out of Crisis
Innovating out of Crisis Shigetaka Komori Chairman and CEO FUJIFILM Holdings Corporation 1 st June, 2015 Business Fields of Fujifilm Group Digital Camera Photo book Optical devise FY2015/3 Digital minilab
More informationStrategic Capital and Business Alliance Between Fujifilm, Taisho Pharmaceutical and Toyama Chemical
Strategic Capital and Business Alliance Between Fujifilm, Taisho Pharmaceutical and Toyama Chemical February 26, 2008 FORWARD-LOOKING STATEMENTS Forward-looking statements such as those relating to earnings
More informationNomura Investment Forum 2012
Shigetaka Komori Chairman, Representative Director and CEO December 4, 2012 FORWARD-LOOKING STATEMENTS Forward-looking statements such as those relating to earnings forecasts and other projections contained
More informationAjinomoto s Pharma-related Business employing Leading-Edge Bioscience and Fine Chemical Technologies
Ajinomoto s Pharma-related Business employing Leading-Edge Bioscience and Fine Chemical Technologies June 8, 2017 Hiroshi Fukushi Member of the Board & Corporate Senior Vice President General Manager,
More informationOutline of the Business Alliance
Notification with Respect to the Basic Agreement Between FUJIFILM Holdings Corporation, Taisho Pharmaceutical Co., Ltd. and Toyama Chemical Co., Ltd. Regarding a Strategic Capital and Business Alliance
More informationTsumura to Hold Presentation on Vision for Business in China
NEWS RELEASE Name of Listed Company Representative Contact TSUMURA & CO. Terukazu Kato President & Representative Director February 14, 2018 (Code: 4540 First Section of the Tokyo Stock Exchange) Noboru
More informationKonica Minolta to Acquire Ambry Genetics (US)
Konica Minolta to Acquire Ambry Genetics (US) Full-fledged Entry into Precision Medicine July 6, 2017 0 1. Transaction Details and Positioning in KM s Strategy 2. Full-fledged Entry into Precision Medicine
More informationFujifilm s Initiatives in Regenerative Medicine
Fujifilm s Initiatives in Regenerative Medicine Shigetaka Komori Chairman and CEO FUJIFILM Holdings Corporation March 30, 2015 Priority Business: Healthcare Expand business with focus on six core business
More informationAbout the Fujifilm Group 2. Management Message 16. Message from the CEO 16 Interview with the COO 20. Corporate Governance 24. Business Activities 36
CONTENTS About the Fujifilm Group 2 Value Creation Process 3 The Fujifilm Group s Value Creation History 4 Business Portfolio and Competitive Advantages 6 Financial Highlights 8 New CSR Plan / New Medium-Term
More informationA Shimadzu Brand with a Committed Worldwide Client Base
Outline of the New Medium-Term Management Plan (2008 2010) A Shimadzu Brand with a Committed Worldwide Client Base Towards a Truly Global Business March 24, 2008 Hattori Shigehiko President and CEO 1 I.
More informationTecan Group 34 th Annual J.P. Morgan Healthcare Conference DR. DAVID MARTYR, CEO JANUARY 14, 2016 SAN FRANCISCO, USA
Tecan Group 34 th Annual J.P. Morgan Healthcare Conference DR. DAVID MARTYR, CEO JANUARY 14, 2016 SAN FRANCISCO, USA Safe Habor Statement All statements in this presentation not referring to historical
More informationFUJIFILM Holdings to own 50.1% of Xerox Corporation s shares, and the combination of Fuji Xerox and Xerox Corporation
FUJIFILM Holdings to own 50.1% of Xerox Corporation s shares, and the combination of Fuji Xerox and Xerox Corporation Shigetaka Komori Chairman and CEO, FUJIFILM Holdings Corporation January 31, 2018 FORWARD-LOOKING
More informationPresentation for IR Meeting
Q1 FY2018 - Apr 1, 2018 to Jun 30, 2018 - Presentation for IR Meeting July 31, 2018 Key points of the first quarter of fiscal 2017 In the 1Q (April to June) of FY2018 sales and operating profit increased
More informationBD Strategy Overview. Advancing the world of health. Vincent A. Forlenza Chairman, Chief Executive Officer and President
BD Strategy Overview Advancing the world of health Vincent A. Forlenza Chairman, Chief Executive Officer and President BD IS AT THE VERY BEGINNING OF AN AMAZING JOURNEY WHERE WE CAN HAVE A PROFOUND IMPACT
More informationFujifilm Group - Business Overview
Fujifilm Group - Business Overview Nov. 2017 FORWARD-LOOKING STATEMENTS Forward-looking statements, such as those relating to earnings forecasts and other projections contained in this material, are management
More informationEarnings of FY2018/3 3Q
Earnings of Jan. 31, 2018 FORWARD-LOOKING STATEMENTS Forward-looking statements, such as those relating to earnings forecasts and other projections contained in this material, are management s current
More informationKonica Minolta to Acquire Invicro (US)
Konica Minolta to Acquire Invicro (US) Acceleration of expansion of precision medicine business Offering new value for drug discovery and development in immuno-oncology and neurodegenerative disease September
More informationYY/T INDUSTRY STANDARD OF THE PEOPLE S REPUBLIC OF CHINA
Translated English of Chinese Standard: YY/T1176-2010 Translated by: www.chinesestandard.net Wayne Zheng et al. Email: Sales@ChineseStandard.net ICS 11.100 YY C 44 INDUSTRY STANDARD OF THE PEOPLE S REPUBLIC
More informationMitsubishi Chemical Holdings to Establish Life Science Institute, Inc.
February 6, 2014 Mitsubishi Chemical Holdings Corporation Mitsubishi Chemical Holdings to Establish Life Science Institute, Inc. Mitsubishi Chemical Holdings Corporation (MCHC; Chiyoda-ku, Tokyo; Yoshimitsu
More information34 th Annual J.P. Morgan Healthcare Conference
34 th Annual J.P. Morgan Healthcare Conference Vincent A. Forlenza Chairman, Chief Executive Officer and President January 13, 2016 Forward-Looking Statements These materials include forward-looking statements
More informationHigh Performance Plastics (HPP) Company
Sekisui Chemical Integrated Report 217 25 High Performance Plastics (HPP) Company Business Overview The s strengths are its original fine particle, adhesion, precise synthesis, and other technologies upon
More informationCreating Corporate Value
Revenue Breakdown by Business Segment Fine Chemicals and Other Products Business 37.1% Elastomers 49.2% Plastics 13.7% Petrochemical Products Business Creating Corporate Value The three strategic domains
More informationUK & Japanese Biomedical Engineering Collaborations. Anil Vaidya Life Science Specialist, JETRO
UK & Japanese Biomedical Engineering s Anil Vaidya Life Science Specialist, JETRO Japan Land of Innovative Engineering Yamaha s Motorcycling Robot Toshiba Developing Vegetable Factories Maglev Train to
More informationPerkinElmer, Inc. JP Morgan Global Healthcare Conference. Robert Friel, Chairman and CEO January 14, 2015 HUMAN HEALTH ENVIRONMENTAL HEALTH
PerkinElmer, Inc JP Morgan Global Healthcare Conference Robert Friel, Chairman and CEO January 14, 2015 HUMAN HEALTH ENVIRONMENTAL HEALTH 2014 PerkinElmer FACTORS AFFECTING FUTURE PERFORMANCE & NON-GAAP
More informationThanks, Bill. Good morning, everyone, and thanks for joining us.
Cabot Microelectronics Corporation 2007 Third Fiscal Quarter Earnings Report July 26, 2007 Good morning. This is Bill Johnson, Vice President and Chief Financial Officer for Cabot Microelectronics Corporation.
More informationKonica Minolta and INCJ Agree to Acquire Ambry Genetics in a Deal Valued at US$1 billion
News Release Konica Minolta and INCJ Agree to Acquire Ambry Genetics in a Deal Valued at US$1 billion Advances Konica Minolta strategy to establish a leadership position in precision medicine Contributes
More informationChina s Strategic Emerging Industries and Their Potential Impacts on MNCs
China s Strategic Emerging Industries and Their Potential Impacts on MNCs Benjamin Bai Partner Allen & Overy LLP January 2013 Allen & Overy 2013 Allen & Overy 2013 South China Morning Post, August 28,
More informationCreating, Saving and Storing. Fast, Fine and Beautiful. Telecommunications. Environment & Energy. Main Products Circuit Connecting Films for Displays
Focused Business Fields Focused Business Fields Creating, Saving and Storing Fast, Fine and Beautiful Telecommunications Environment & Energy Through state-of-the-art technology development for materials
More informationOverview of the current Japanese biotech industry and investment outlook
Overview of the current Japanese biotech industry and investment outlook Daiwa SMBC Capital Co.,Ltd Hiroki Narita Deputy General Manager E-mail:narita@daiwasmbc-cap.co.jp Biotechnology Market in Japan
More informationCyclic Innovation for Clinical Empowerment. (CiCLE)
Cyclic Innovation for Clinical Empowerment (CiCLE) Japan Agency for Medical Research and Development (AMED), National Research and Development Agency 1 Cyclic Innovation for Clinical Empowerment (CiCLE)
More informationCorporate Philosophy and Vision, Brand Mark, Business Management Goals and Other Policies of Mitsubishi Tanabe Pharma Corporation
May 16, 2007 Press Release Tanabe Seiyaku Co., Ltd. Mitsubishi Pharma Corporation Corporate Philosophy and Vision, Brand Mark, Business Management Goals and Other Policies of Mitsubishi Tanabe Pharma Corporation
More informationRealizing the Future that Regenerative Medicine Will Open
470 Hitachi Review Vol. 65 (2016), No. 9 Featured Articles Realizing the Future that Regenerative Medicine Will Open Shizu Takeda, Ph.D. OVERVIEW: Regenerative medicine is an innovative approach to medicine
More informationAcquisition of COSMOTEC
Acquisition of COSMOTEC Reference Material September 2017 Copyright 2017 M3, Inc. All rights reserved. The following presentation contains forecasts, future plans, management targets and other forward-looking
More informationBuilding the Europe of Knowledge
Building the Europe of Knowledge 7 th Framework Programme 2007-2013 Nanotechnology! All information preliminary! FP7 1. Capacities: Infrastructures 2. People: Erasmus, Marie-Curie 3. Ideas: ERC 4. Cooperation:
More informationFull Acquisition of Yusen Logistics Co., Ltd.
Full Acquisition of Logistics Co., Ltd. October 31, 2017 2016. NYK Group. All rights 2016. reserved. NYK Group. All rights reserved. Transaction Overview Overview Nippon s full acquisition of Logistics
More informationJefferies 2018 Global Healthcare Conference. June 7, 2018
Jefferies 2018 Global Healthcare Conference June 7, 2018 Forward-Looking Statements Statements in this presentation regarding the future financial and operating results, outlook, growth, prospects, business
More informationEvonik Birmingham Laboratories
Evonik Birmingham Laboratories An integrated CDMO for advanced parenterals with a portfolio of delivery technologies, formulation development services and GMP manufacturing Evonik Birmingham Laboratories
More informationMELISSA STAHL RESEARCH MANAGER THE HEALTH MANAGEMENT ACADEMY
TECHNOLOGY INTEGRATION AT LEADING HEALTH SYSTEMS VENDOR NEUTRAL ARCHIVES AT INDIANA UNIVERSITY HEALTH MELISSA STAHL RESEARCH MANAGER THE HEALTH MANAGEMENT ACADEMY The Academy The Health Management Academy
More informationClinical Supply Packaging for Biological Products
Clinical Supply Packaging for Biological Products Part 2 of the Clinical Supply Knowledge Share Series: Understanding and Delivering your Global Clinical Supply Chain Almac Clinical Services Clinical Supply
More informationScientific Solutions Business Strategy
Scientific Solutions Business Strategy Toshihiko Okubo Division Manager Scientific Solutions Business Strategy Division Olympus Corporation March 30, 2016 Todayʼs Agenda 1.Business Overview 2.Recognition
More informationExecution Status of Law concerning the Evaluation and Regulation of Manufacture, etc. of Chemical Substances (CSCL) (2006)
Execution Status of Law concerning the Evaluation and Regulation of Manufacture, etc. of Chemical Substances (CSCL) (2006) July 20, 2007 Chemical Safety Office, Chemical Management Policy Division, Manufacturing
More informationBasic Information. I.1 If your company performs biotechnology research and development, uses a. The Categories of Biotechnology Applications.
APPENDIX 2 SURVEY QUESTIONNAIRE Part I. Basic Information I.1 If your company performs biotechnology research and development, uses a biotechnology process in manufacturing, or produces research tools,
More informationSanten Acquisition of InnFocus, Developer of MicroShunt Glaucoma Implant Device
Santen Acquisition of InnFocus, Developer of MicroShunt Glaucoma Implant Device Akira Kurokawa President & CEO August 2, 2016 Copyright 2016 Santen Pharmaceutical Co., Ltd. All rights reserved. 1 External
More informationUrban Infrastructure & Environmental Products (UIEP) Company
Sekisui Chemical Integrated Report 218 President s Policy Get on the track for Growth Expanding business Field with Competitive Technology and Products 1. Expand Sales of Growth Products by Concentrating
More informationWelcome to all Delegates Biotechnology for Pharmaceutical and Health Classification of Biotechnology Conventional Is a technique that makes use of living organism for specific purpose eg: bread/cheese
More informationFinancial Results for FY2017 and Strategy
Financial Results for FY2017 and Strategy Recruit Holdings Co., Ltd. Masumi Minegishi President, CEO, and Representative Director Keiichi Sagawa CFO and Senior Managing Corporate Executive Officer May
More informationYY/T PROFESSIONAL STANDARD OF THE PEOPLE S REPUBLIC OF CHINA 中华人民共和国医药行业标准. Total Prostate Specific Antigen (t-psa) Quantitative
ICS 11.100 C 44 PROFESSIONAL STANDARD OF THE PEOPLE S REPUBLIC OF CHINA 中华人民共和国医药行业标准 Total Prostate Specific Antigen (t-psa) Quantitative Detection Reagent (Kit) (Chemiluminescent Immimoassay) 总前列腺特异性抗原
More informationCompany presentation Full year 2016
Company presentation Full year 2016 SOL Group at a glance Founded in 1927, is an Italian based multinational company present in 28 countries with more of 3,200 people employed. Two core, separated but
More informationNEW ERA OF A HYDROGEN ENERGY SOCIETY
METI NEW ERA OF A HYDROGEN ENERGY SOCIETY October 19, 2015 Energy Conservation and Renewable Energy Department Director, and Fuel Cell Promotion Office Chihiro Tobe Dissemination of the Use of Energy Past
More informationA full-service CRO with integrated early-stage capabilities
CHARLES RIVER TO ACQUIRE ARGENTA and BIOFOCUS A full-service CRO with integrated early-stage capabilities James C. Foster Chairman, President & CEO Thomas F. Ackerman Executive Vice President & CFO March
More informationChina Diagnostic Reagent Industry Report, Nov. 2013
China Diagnostic Reagent Industry Report, 2013-2015 Nov. 2013 STUDY GOAL AND OBJECTIVES This report provides the industry executives with strategically significant competitor information, analysis, insight
More informationMidterm Management Plan
Midterm Management Plan From FY 2014 to FY 2016 Become an Innovative Company Contributing to Growth of Global Customers 2014.3.26 Shimadzu Corporation Akira Nakamoto, President and Chief Executive Officer
More information33.8% Revenue Breakdown by Business Segment. Elastomers 51.6% Plastics 14.6% Petrochemical Products Business JSR CORPORATION ANNUAL REPORT 2014
> The JSR Group s objective is to secure stable earnings from the Petrochemical Products Business (Elastomers and ) and Fine Chemicals business and increase future profitability by positioning the
More informationLife Sciences Debashis Ghosh. 1 Copyright 2016 Tata Consultancy Services Limited
Life Sciences Debashis Ghosh 1 Copyright 2016 Tata Consultancy Services Limited From biology, chemistry and anatomy to data, analytics and technology Analytics driven Genomics Research We identify disease
More informationMitsubishi Chemical Group KAKUSHIN-Phase1
Mitsubishi Chemical Group KAKUSHIN-Phase1 November 14, 2002 1.. Management Issues and Policies 2. Gist of KAKUSHIN - Phase 1 1 Plan (1) Portfolio Reform (2) Improvement of Financial Position (3) R&TD Policy
More informationYY/T PROFESSIONAL STANDARD OF THE PEOPLE S REPUBLIC OF CHINA 中华人民共和国医药行业标准. Automatic Luminescence Immunoassay Analyzer 全自动发光免疫分析仪
ICS 11.100 C 44 PROFESSIONAL STANDARD OF THE PEOPLE S REPUBLIC OF CHINA 中华人民共和国医药行业标准 Automatic Luminescence Immunoassay Analyzer 全自动发光免疫分析仪 Issued on December 30, 2009 Implemented on June 1, 2011 Issued
More informationCompany Profile. German-Taiwan Biotech Seminar 6 November 2017
Company Profile German-Taiwan Biotech Seminar 6 November 2017 Our Mission Bayer: Science For A Better Life A growing and aging world population requires an adequate supply of food and improved medical
More informationWind Farm Technologies
Wind Farm Technologies Dr. LIU Yongqian Professor, Renewable Energy School North China Electric Power University No.2 BeiNong Road, HuiLongGuan, ChangPing, Beijing, 102206 China Email: yqliu@ncepu.edu.cn
More informationProgenika Biopharma Group
Progenika Biopharma Group Foro del emprendedor BCN2011 5 Septiembre 2011 Progenika Biopharma Pioneering Personalized Medicine Progenika, leading company in Personalized Medicine Progenika is a leading
More information1.Bioinstrumentation *SIMPLE AND QUICK GENETIC TESTING DEVICES (INFECTION & OTHERS, ON MARKET<OM> IN JAPAN)
R & D, Commercialization projects 1.Bioinstrumentation *SIMPLE AND QUICK GENETIC TESTING DEVICES (INFECTION & OTHERS, ON MARKET IN JAPAN) *DOWNSIZED SYSTEM FOR MEASURING RESPIRATORY SYSTEM IMPEDANCE
More informationGlobal and China Biopharmaceutical Industry Report, 2010
Global and China Biopharmaceutical Industry Report, 2010 In recent years, biopharmaceutical industry has been the fastest growing sector in the global pharmaceutical industry. From 1998 to 2009, the compound
More informationMay 14, 2014 CGI Announces Acquisition of BioServe India
Empowering Personalized Cancer Treatment May 14, 2014 CGI Announces Acquisition of BioServe India CGI and BioServe India Enter Into Acquisition Agreement On May 14 th, 2014 Cancer Genetics, Inc. and BioServe
More informationWe work with passion, using advanced technologies, to transform life science into new possibilities for our customers
We work with passion, using advanced technologies, to transform life science into new possibilities for our customers Business Update: First Quarter 2009 23 April 2009 Stefan Borgas Chief Executive Officer
More information6. Vision 3: Leading the Japanese economy forward as a high value-added industry"
6. Vision 3: Leading the Japanese economy forward as a high value-added industry" Strategic points for realizing the vision Streamlining and rationalization R&D to create innovative drugs Proactively introducing
More informationCreative Hybrid Chemistry For a Better Tomorrow
Creative Hybrid Chemistry For a Better Tomorrow December 12, 2011 Masakazu Tokura President Agenda Overview of FY2011 Performance 2 Sumitomo Chemical s Current Position 6 Review of Major Strategic Initiatives
More informationGap Analysis for Drug Development Process
Gap Analysis for Drug Process Dr. Jia Ming Chang AM4 Preclinical Animal Testing Center Institute for Drug Evaluation Platform Center for Biotechnology Benefit of Gap Analysis Gap analysis service support
More informationHuman ips/es Cell Technology and Its Application to Toxicology Testing
Human ips/es Cell Technology and Its Application to Toxicology Testing -Especially focusing on in vitro cardiac function toxicity- Atsushi Sanbuissho, PhD Daiichi Sankyo Co., Ltd. Kenji Yasuda, Prof Tokyo
More informationTo meet the challenge of providing safe, cost-effective medicines for the world s largest
An Executive Summary Biopharma in China: New Initiatives, New Opportunities To meet the challenge of providing safe, cost-effective medicines for the world s largest population, the government of China
More informationGetting to the Factory of the Future
Patient-Specific Cell Therapy Getting to the Factory of the Future Robert A. Preti, PhD Chief Executive Officer and President, PCT General Manager, Global Regenerative Medicine Business Sector, Hitachi
More informationInnovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing
Innovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing Overview Serving biotech and pharma community since 1998 Proven track record of advancing small molecules from
More informationMediSapiens Ltd. Because data is not knowledge. 4th of November Sami Kilpinen, Ph.D Co-founder, CEO MediSapiens Ltd
4th of November 2014 MediSapiens Ltd Because data is not knowledge Sami Kilpinen, Ph.D Co-founder, CEO MediSapiens Ltd Copyright 2014 MediSapiens Ltd. All rights reserved. medisapiens.com MediSapiens Brief
More informationPatenting biotechnological inventions
Patenting biotechnological inventions Izabela Milczarek, PhD, Specialist in Patents Department at Patpol Patpol - European and Polish Patent and Trade Mark Attorneys What is biotechnology? The 20 th century
More informationBusiness Update: First Quarter 2007
Conference Call, April 19 th, 2007 Business Update: First Quarter 2007 Stefan Borgas, CEO Disclaimer Certain matters discussed in this presentation may constitute forwardlooking statements. These statements
More information--> Buy True-PDF --> Auto-delivered in 0~10 minutes. YY/T Translated English of Chinese Standard: YY/T
Translated English of Chinese Standard: www.chinesestandard.net Buy True-PDF Auto-delivery. Sales@ChineseStandard.net PHARMACEUTICAL INDUSTRY STANDARD YY OF THE PEOPLE S REPUBLIC OF CHINA ICS 11.100 C
More informationThe main goal of the strategic partnership is the development of innovative, all-natural cosmetic active ingredients and aroma molecules.
PRESS RELEASE Symrise: Strategic partnership with BRAIN and AnalytiCon Discovery (Holzminden/Potsdam/Zwingenberg, April 2, 2007) Symrise GmbH & Co. KG, the world s fourth-largest supplier of fragrance
More informationConference Exhibitors
Conference Exhibitors CSM Executive and the 2018 Manitoba Local Organizing Committee would like to thank the following organizations for exhibiting and supporting the Canadian Society of Microbiologists
More informationReal solutions for real-world problems.
Digital Health Real solutions for real-world problems. Today, it costs around $2.6 billion and takes between 10 and 15 years to develop a new drug. 1 Despite the enormity of this investment, once the drug
More informationGlobal Contract Research Organization (CRO) Market: Size, Trends & Forecasts ( ) November 2017
Global Contract Research Organization (CRO) Market: Size, Trends & Forecasts (2017-2021) November 2017 Global Contract Research Organization (CRO) Market : Coverage Executive Summary and Scope Introduction/Market
More informationCreating Corporate Value
11 Creating Corporate Value Bioprocess Display The three strategic domains for JSR Group are petrochemical products, fine chemicals, and life sciences. In each of these areas, we are developing business
More informationGENE EXPRESSION REAGENTS MARKETS (SAMPLE COPY, NOT FOR RESALE)
TriMark Publications April 2007 Volume: TMRGER07-0401 GENE EXPRESSION REAGENTS MARKETS (SAMPLE COPY, NOT FOR RESALE) Trends, Industry Participants, Product Overviews and Market Drivers TABLE OF CONTENTS
More informationJefferies 2015 Global Healthcare Conference June 3, 2015
Jefferies 2015 Global Healthcare Conference June 3, 2015 Forward-Looking Statements This document may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act
More informationMasaki Muto MD PhD Chairman, Japan Society of Generic Medicines (Professor, International University of Health and Welfare Graduate School )
Masaki Muto MD PhD Chairman, Japan Society of Generic Medicines (Professor, International University of Health and Welfare Graduate School ) Agenda Part 1 Current Status of Generics Market in Japan Part
More informationWe make drugs smarter
We make drugs smarter Brookwood Pharmaceutical Services WE MAKE DRUGS SMARTER Using our 40 years of experience, our state of the art facilities and our IP protected technologies, we leverage existing capabilities
More informationSources: Tokyo Institute of Technology City of Kawasaki. For immediate release: August 4, 2017
PRESS RELEASE Sources: Tokyo Institute of Technology City of Kawasaki For immediate release: August 4, 2017 Subject line: Tokyo Institute of Technology and Kawasaki City are Combining Forces in R&D on
More informationAlmac Overview.
Almac Overview www.almacgroup.com 2 Welcome to Almac 3 Who is Almac? Almac is a world leading drug development & commercial services company; providing an expanding array of innovative solutions worldwide
More informationMASTER IN PHARMACEUTICAL SCIENCES (Thesis Track)
MASTER IN PHARMACEUTICAL SCIENCES (Thesis Track) I. GENERAL RULES CONDITIONS: Plan Number 1 \ 12 70 2005 T 1. This plan conforms to the valid regulations of the programs of graduate studies. 2. Areas of
More informationCMP MARKETS & VALUE CHAIN PERSPECTIVES
CMP MARKETS & VALUE CHAIN PERSPECTIVES MICHAEL CORBETT MANAGING PARTNER LINX CONSULTING MCORBETT@LINX-CONSULTING.COM A PRESENTATION FOR THE CMP USERS GROUP JULY 17, 2007 LINX CONSULTING OUTLINE 1. Introduction
More informationFinancial Results for the Fiscal Year Ended March 31, April 27, 2018 NEC Corporation (https://www.nec.com/en/global/ir)
Financial Results for the Fiscal Year Ended March 31, 2018 April 27, 2018 NEC Corporation (https://www.nec.com/en/global/ir) Index Ⅰ. Financial Results for Ⅱ. Financial Forecasts for FY19/3 Ⅲ. Progress
More informationBEYOND 300 (FY FY2020)
Mid-term Management Plan BEYOND 300 (FY2018 - FY2020) ADEKA Corporation Stock Code: 4401 1 Table of Contents 1. Review of STEP 3000-II Overview Financial Performance Management Indexes Summary 2. ADEKA
More informationMARKETS & CUSTOMERS. Progressing globalization. Evolving markets
Peptides are used worldwide in medical research. They contribute immensely to the understanding of diseases and have proven to be effective in medicinal products. Today, peptides can be produced at low
More informationM3, Inc. Presentation Material. July Copyright 2017 M3, Inc. All rights reserved.
M3, Inc. Presentation Material July 2017 Copyright 2017 M3, Inc. All rights reserved. The following presentation contains forecasts, future plans, management targets and other forward-looking projections
More informationFor Early Access of Innovative Medical Devices to Patients
Summit of Heads of Medicines Regulatory Agencies Symposium For Early Access of Innovative Medical Devices to Patients October 27 th, 2017 Masaya Watanabe Chairman, The Japan Federation of Medical Devices
More informationFY2017 to FY2019 Medium-Term Management Plan. March 29, 2017 Shimadzu Corporation President and CEO Teruhisa Ueda
FY2017 to FY2019 Medium-Term Management Plan March 29, 2017 Shimadzu Corporation President and CEO Teruhisa Ueda Contents I. Review of the Previous Plan p.1-4 II. Overview of the New Medium-Term Management
More informationNew strategic initiative at Wacom Shift focus to profitability, grow corporate value in the medium term
For reference (*) March 14, 2017 New strategic initiative at Wacom Shift focus to profitability, grow corporate value in the medium term 1. Background In April 2015, Wacom unveiled its Strategic Business
More informationPresentation to Investors. February, 2003
Presentation to Investors February, 2003 Table of Contents 1. Review of Latest Performance 2. KAKUSHIN Plan Appendix Forward-Looking Statements: This material contains forward-looking statements which
More informationPfizer Completes Acquisition of Hospira
For immediate release: September 3, 2015 Media Contact: Joan Campion (212) 733-2798 Investor Contact: Chuck Triano (212) 733-3901 Pfizer Completes Acquisition of Hospira Creates a leading Global Established
More informationIn the Midst of Changing Times Revolutionary Technology and Products Driving Corporate Evolution
The Story of Sumitomo Chemical Trajectory Since Its Founding In the Midst of Changing Times Revolutionary Technology and Products Driving Corporate Evolution 1915-1945- Building a Foundation as a Chemical
More informationThe Microsoft Conference 2014 ROOM F
The Microsoft Conference 2014 ROOM F 既存社内システムの問題点と対策 Dynamics AX とは? マイクロソフト製品との広範囲な相互運用性を持つ柔軟性の高い操作性を重視したグローバル ERP 同一製品内で複数の業種機能に対応可能 36 ヵ国の税法 41 言語 複数通貨を 1 導入で実現 柔軟なカスタマイズを可能にする統合開発環境と階層構造 AX クライアントによるシンプルな操作性と
More informationGene Techno Science Co., Ltd.
Unlimited drug discovery from the beginning Ticker symbol: 4584 Gene Techno Science Co., Ltd. Financial Results for the Fiscal Year Ended March 2018 May 16, 2018 1 2 Corporate overview Chief Executive
More information